{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:36:21Z","timestamp":1791844581193,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.ppat.1007552","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000}}],"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(81630061"],"award-info":[{"award-number":["(81630061"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473255"],"award-info":[{"award-number":["81473255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2018ZX10301103"],"award-info":[{"award-number":["2018ZX10301103"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2017-I2M-1-014"],"award-info":[{"award-number":["2017-I2M-1-014"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1007552","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T18:45:37Z","timestamp":1549305937000},"page":"e1007552","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":48,"title":["Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques"],"prefix":"10.1371","volume":"15","author":[{"given":"Huihui","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2048-6696","authenticated-orcid":true,"given":"Yuxian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2336","article-title":"HIV drug development: the next 25 years","volume":"6","author":"C Flexner","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(07)61052-6","article-title":"HIV entry inhibitors","volume":"370","author":"JA Este","year":"2007","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"T Matthews","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"RM Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3390\/v2051069","article-title":"HIV-1 Entry, Inhibitors, and Resistance","volume":"2","author":"MA Lobritz","year":"2010","journal-title":"Viruses"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2174\/1381612811319100004","article-title":"Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion","volume":"19","author":"Y He","year":"2013","journal-title":"Curr Pharm Des"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"P Ingallinella","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/jac\/dkt529","article-title":"Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure","volume":"69","author":"MT Augusto","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/QAD.0000000000001073","article-title":"Development of potent and long-acting HIV-1 fusion inhibitors","volume":"30","author":"H Chong","year":"2016","journal-title":"AIDS"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e00288","DOI":"10.1128\/JVI.00288-17","article-title":"A Lipopeptide HIV-1\/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity","volume":"91","author":"H Chong","year":"2017","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1096\/fj.12-215111","article-title":"Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1","volume":"26","author":"A Ashkenazi","year":"2012","journal-title":"FASEB J"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e1000509","DOI":"10.1371\/journal.ppat.1000509","article-title":"Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action","volume":"5","author":"Y Wexler-Cohen","year":"2009","journal-title":"PLoS Pathog"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1096\/fj.07-8582com","article-title":"Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition","volume":"21","author":"Y Wexler-Cohen","year":"2007","journal-title":"FASEB J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"21012","DOI":"10.1074\/jbc.M212773200","article-title":"C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV\/SIMIAN immunodeficiency virus-induced membrane fusion","volume":"278","author":"SG Peisajovich","year":"2003","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1074\/jbc.M004113200","article-title":"Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage","volume":"276","author":"Y Kliger","year":"2001","journal-title":"J Biol Chem"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e00831","DOI":"10.1128\/JVI.00831-17","article-title":"Enfuvirtide (T20)-based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implication for Viral Entry and Inhibition","volume":"91","author":"X Ding","year":"2017","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e01088","DOI":"10.1128\/JVI.01088-18","article-title":"Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against HIV-1, HIV-2, and Simian Immunodeficiency Virus","volume":"92","author":"H Chong","year":"2018","journal-title":"J Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e00775","DOI":"10.1128\/JVI.00775-18","article-title":"Design of Novel HIV-1\/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models","volume":"92","author":"H Chong","year":"2018","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"K Madsen","year":"2007","journal-title":"J Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1096\/fj.09-151704","article-title":"Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain","volume":"24","author":"Y Wexler-Cohen","year":"2010","journal-title":"FASEB J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: First Global Approval","volume":"78","author":"S Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"C Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of viral membrane fusion and its inhibition","volume":"70","author":"DM Eckert","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"DC Chan","year":"1998","journal-title":"Cell"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"11129","DOI":"10.1128\/JVI.01060-08","article-title":"Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition","volume":"82","author":"Y He","year":"2008","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"25631","DOI":"10.1074\/jbc.M703781200","article-title":"Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry","volume":"282","author":"Y He","year":"2007","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"34558","DOI":"10.1074\/jbc.M112.390393","article-title":"The M-T hook structure is critical for design of HIV-1 fusion inhibitors","volume":"287","author":"H Chong","year":"2012","journal-title":"J Biol Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"20281","DOI":"10.1074\/jbc.M112.354126","article-title":"Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652","volume":"287","author":"H Chong","year":"2012","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1128\/JVI.00319-08","article-title":"Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors","volume":"82","author":"Y He","year":"2008","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/QAD.0000000000000683","article-title":"Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target","volume":"29","author":"Z Qiu","year":"2015","journal-title":"AIDS"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1073\/pnas.0807335105","article-title":"Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains","volume":"105","author":"Y He","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/QAD.0000000000000498","article-title":"Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket","volume":"29","author":"H Chong","year":"2015","journal-title":"AIDS"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e01839","DOI":"10.1128\/JVI.01839-16","article-title":"A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus","volume":"91","author":"S Xiong","year":"2017","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1074\/jbc.RA118.001729","article-title":"Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus","volume":"293","author":"Y Zhu","year":"2018","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"12703","DOI":"10.1074\/jbc.RA118.003538","article-title":"Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor","volume":"293","author":"D Yu","year":"2018","journal-title":"J Biol Chem"},{"key":"ref37","first-page":"e02044","article-title":"Mechanism of HIV-1 Resistance to an Electronically Constrained alpha-Helical Peptide Membrane Fusion Inhibitor","volume":"92","author":"X Wu","year":"2018","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"12467","DOI":"10.1128\/JVI.01741-15","article-title":"Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket","volume":"89","author":"Y Su","year":"2015","journal-title":"J Virol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1128\/JVI.00373-15","article-title":"Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket","volume":"89","author":"Y Su","year":"2015","journal-title":"J Virol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"10785","DOI":"10.1128\/JVI.05331-11","article-title":"Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function","volume":"85","author":"D Eggink","year":"2011","journal-title":"J Virol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"26618","DOI":"10.1074\/jbc.M112.381079","article-title":"Structural basis of potent and broad HIV-1 fusion inhibitor CP32M","volume":"287","author":"X Yao","year":"2012","journal-title":"J Biol Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1074\/jbc.M111.317883","article-title":"Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide","volume":"287","author":"X Yao","year":"2012","journal-title":"J Biol Chem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1093\/jac\/dku183","article-title":"The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance","volume":"69","author":"H Chong","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1096\/fj.12-222547","article-title":"Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1","volume":"27","author":"H Chong","year":"2013","journal-title":"FASEB J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fcimb.2018.00051","article-title":"Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket","volume":"8","author":"X Zhang","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0000000000001979","article-title":"Structural and functional characterization of HIV-1 cell fusion inhibitor T20","volume":"33","author":"X Zhang","year":"2019","journal-title":"AIDS"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"CT Wild","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"S Jiang","year":"1993","journal-title":"Nature"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"JP Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1083\/jcb.140.2.315","article-title":"Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41","volume":"140","author":"I Munoz-Barroso","year":"1998","journal-title":"J Cell Biol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"14337","DOI":"10.1021\/bi0612521","article-title":"Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence","volume":"45","author":"M Lorizate","year":"2006","journal-title":"Biochemistry"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1074\/jbc.M411141200","article-title":"Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120","volume":"280","author":"S Liu","year":"2005","journal-title":"J Biol Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1128\/JVI.78.10.5448-5457.2004","article-title":"CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor","volume":"78","author":"W Yuan","year":"2004","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"16249","DOI":"10.1073\/pnas.252469399","article-title":"Sensitivity of HIV-1 to entry inhibitors correlates with envelope\/coreceptor affinity, receptor density, and fusion kinetics","volume":"99","author":"JD Reeves","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1128\/JVI.75.18.8605-8614.2001","article-title":"Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor","volume":"75","author":"CA Derdeyn","year":"2001","journal-title":"J Virol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"CA Derdeyn","year":"2000","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1007552","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1007552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T09:30:55Z","timestamp":1589016655000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1007552"}},"subtitle":[],"editor":[{"given":"Guido","family":"Silvestri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1007552","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.ppat.1007552","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]}}}